Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | PTGS2 |
| Gene Name: | PTGS2 |
| Protein Full Name: | Prostaglandin G/H synthase 2 |
| Alias: | COX2; Cyclooxygenase-2; PGH synthase 2; PGH2; PGHS-2; PHS II; Prostaglandin G/H synthase 2; Prostaglandin G/H synthase and cyclooxygenase; Prostaglandin H2 synthase 2; Prostaglandin-endoperoxide synthase 2 |
| Mass (Da): | 68996 |
| Number AA: | 604 |
| UniProt ID: | P35354 |
| Locus ID: | 5743 |
| COSMIC ID: | PTGS2 |
| Gene location on chromosome: | 1q31.1* |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 19777 |
| Percent of cancer specimens with mutations: | 0.7 |
| Normal role description: | PTGS2 is a metabolic enzyme that functions in prostaglandin synthesis by mediating the formation of prostaglandins from arachidonate. It functions both as as a dioxygenase and as a peroxidase, and may also play a role in mediating inflammation and in prostanoid signalling in activity-dependent plasticity. PTGS2 (COX2) is the target of NSAID's such as aspirin. The gene has been implicated in mitogenesis, as well as in several pathophysiological processes, including inflammation, angiogenesis, and tumorigenesis. It has been found to be over-expressed in a number of cancers. |
| Commentary on involvement of protein in cancer: | * chromosome location = 1q25.2-q25.3 according to NCBI Gene. 1/45 CNS samples, and 1 pharyngeal sample/5 total UAT samples was also mutated (mis-sense). Only 1 ovarian tumour sample was included in Sanger COSMIC. |